ArticleFrontiers in oncology2025
Predicting modelling for early diagnosis in early myeloproliferative neoplasms, not otherwise specified. Evidence from a machine learning study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial intelligence in neurocardiology: decoding brain-heart network interactions for clinical and translational insights.Frontiers in neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recently, artificial intelligence (AI) has become a valuable tool for diagnosing and predicting outcomes in blood disorders. Whole Slide Imaging (WSI) of bone marrow biopsies (BMBs) offers detailed, high-resolution views of cells and tissues; its adoption may improve the resources dedicated to the interpretation of BMB with suspected early myeloproliferative neoplasms (MPNs). Methods: We collected a retrospective dataset of H&E-stained BMBs from 88 patients diagnosed with MPN, divided into three groups: 19 with prefibrotic primary myelofibrosis (pre-PMF), 30 with polycythemia vera (PV), and 39 with essential thrombocythemia (ET). Using AI, we framed this as a three-class classification problem. For each whole slide image, we automatically calculated cellularity and cell density. We extracted morphological features related to megakaryocytes-area, perimeter, and circularity-and summarized them for each patient using statistics like mean, standard deviation, skewness, kurtosis, and entropy. This resulted in 17 features combining nuclear morphology, cell density statistics, and cellularity. After selecting significant features with the Kruskal-Wallis test, we trained a Support Vector Machine (SVM) classifier with 5-fold cross-validation to predict MPN subtypes. We then tested the model on 13 patients with a diagnosis of MPN not otherwise specified (MPN-NOS) to assess its capacity to correctly characterize the diagnosis. Results: The model achieved a mean multiclass Area Under the Curve (AUC) of 0.70 ± 0.01 and an accuracy of 0.60 ± 0.03. When tested on the 13 patients with MPN not otherwise specified (MPN-NOS), the model agreed with pathologists' biopsy classifications 61.5% of the time and with clinical follow-up evaluations 50% of the time. Conclusions: This study represents a first step toward the development of automated tools to support MPN diagnosis, providing potential assistance to haematologists and pathologists in the clinical management of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.